News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rhizen Pharmaceuticals S.A. Announces Preclinical Presentations On RP6530, A Dual PI3K Delta/Gamma Inhibitor, For The Treatment Of Hematological Malignancies At The 55th Annual Meeting Of The American Society of Hematology, 2013


11/19/2013 9:12:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for its clinical lead, RP6530, a novel, dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, in B & T-cell Lymphomas, at the Annual meeting of the American Society of Hematology (ASH) 2013 to be held from December 07-10, at New Orleans, LA.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES